VT3989
vivace therapeutics
['mesothelioma', 'vt3989', 'tead inhibitor']
first-in-class yap/tead inhibitor vt3989 was well-tolerated with durable antitumor responses in patients with advanced malignant mesothelioma, other tumors with nf2 mutations, says dr. timothy yap of first clinical proof-of-concept for drugging the hippo-yap-tead pathway. #aacr23 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789